Low-grade gliomas: management issues

References

• van Veelen ML, Avezaat CJ, Kros JM, van PW. Vecht C. Supratentorial low grade astrocytoma: prognostic factors, dedifferentiation and the issue of early versus late surgery. J. Neurol. Neurosurg. Psychiatr.64, 581–587 (1998).
   PubMed Web of Science ®Google Scholar
• Wessels PH, Weber WE, Raven G et al. Supratentorial grade II astrocytoma: biological features and clinical course. Lancet Neurol.2, 395–403 (2003).
   PubMed Web of Science ®Google Scholar
• Leighton C, Fisher B, Bauman G et al. Supratentorial low-grade glioma in adults: an analysis of prognostic factors and timing of radiation. J. Clin. Oncol.15, 1294–1301 (1997).
   PubMed Web of Science ®Google Scholar
• Henson JW, Gaviani P, Gonzalez RG. MRI in treatment of adult gliomas. Lancet Oncol.6, 167–175 (2005).
   PubMed Web of Science ®Google Scholar
• Barker FG, Chang M, Huhn SL et al. Age and the risk of anaplasia in magnetic resonance-nonenhancing supratentorial cerebral tumors. Cancer80, 936–941 (1997).
   PubMed Web of Science ®Google Scholar
• Shaw E, Arusell R, Scheithauer B et al. Prospective randomized trial of low- versus high-dose radiation therapy in adults with supratentorial low-grade glioma: initial report of a North Central Cancer Treatment Group/Radiation Therapy Oncology Group/Eastern Cooperative Oncology Group study. J. Clin. Oncol.20, 2267–2276 (2002).
   PubMed Web of Science ®Google Scholar
• Kreth FW, Faist M, Rossner R, Volk B, Ostertag CB. Supratentorial World Health Organization grade 2 astrocytomas and oligoastrocytomas. A new pattern of prognostic factors. Cancer79, 370–379 (1997).
   PubMed Web of Science ®Google Scholar
• Castillo M, Smith JK, Kwock L. Correlation of myo-inositol levels and grading of cerebral astrocytomas. AJNR Am. J. Neuroradiol.21, 1645–1649 (2000).
   PubMedGoogle Scholar
• Pirzkall A, Nelson SJ, McKnight TR et al. Metabolic imaging of low-grade gliomas with 3D magnetic resonance spectroscopy. Int. J. Radiat. Oncol. Biol. Phys.53, 1254–1264 (2002).
   PubMedGoogle Scholar
• Law M, Yang S, Wang H et al. Glioma grading: sensitivity, specificity and predictive values of perfusion MR imaging and proton MR spectroscopic imaging compared with conventional MR imaging. AJNR Am. J. Neuroradiol.24, 1989–1998 (2003).
   PubMed Web of Science ®Google Scholar
• Cha S, Tihan T, Crawford F et al. Differentiation of low-grade oligodendrogliomas from low-grade astrocytomas by using quantitative blood-volume measurements derived from dynamic susceptibility contrast-enhanced MR imaging. AJNR Am. J. Neuroradiol.26, 266–273 (2005).
   PubMedGoogle Scholar
• Padma MV, Said S, Jacobs M et al. Prediction of pathology and survival by FDG PET in gliomas. J. Neurooncol.64, 227–237 (2003).
   PubMedGoogle Scholar
• Catalaa I, Henry R, Dillon W P et al. Perfusion, diffusion and spectroscopy values in newly diagnosed cerebral gliomas. NMR Biomed.19, 463–475 (2006).
   PubMed Web of Science ®Google Scholar
• Lote K, Egelan T, Hager B et al. Survival, prognostic factors, and therapeutic efficacy in low-grade glioma: a retrospective study in 379 patients. J. Clin. Oncol.15, 3129–3140 (1997).
   PubMed Web of Science ®Google Scholar
• Laws ER Jr, Taylor WF, Clifton MB, Okazaki H. Neurosurgical management of low-grade astrocytoma of the cerebral hemispheres. J. Neurosurg.61, 665–673 (1984).
   PubMed Web of Science ®Google Scholar
• Bauman G, Lote K, Larson D et al. Pretreatment factors predict overall survival for patients with low-grade glioma: a recursive partitioning analysis. Int. J. Radiat. Oncol. Biol. Phys.45, 923–929 (1999).
   PubMed Web of Science ®Google Scholar
• Pignatti F, Bent M, van den Bent M et al. Prognostic factors for survival in adult patients with cerebral low-grade glioma. J. Clin. Oncol.20, 2076–2084 (2002).
   PubMed Web of Science ®Google Scholar
• Schuurman PR, Troost D, Verbeeten B Jr, Bosch DA. 5-year survival and clinical prognostic factors in progressive supratentorial diffuse ‘low-grade’ astrocytoma: a retrospective analysis of 46 cases. Acta Neurochir. (Wien.)139, 2–7 (1997).
   PubMed Web of Science ®Google Scholar
• Piepmeier JM, Fried I, Makuch R. Low-grade astrocytomas may arise from different astrocyte lineages. Neurosurgery33, 627–632 (1993).
   PubMedGoogle Scholar
• Kleihues P, Cavanee WK. WHO Classificiation: Tumors of the Nervous System. Kleihus P and Cavanee WK (Eds). IARC Press, Lyon, France (2000).
   Google Scholar
• Jaeckle KA, Ballman KV, Rao RD, Jenkins RB, Buckner JC. Current strategies in treatment of oligodendroglioma: evolution of molecular signatures of response. J. Clin. Oncol.24, 1246–1252 (2006).
   PubMed Web of Science ®Google Scholar
• Smith JS, Perry A, Borell TJ et al. Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas and mixed oligoastrocytomas. J. Clin. Oncol.18, 636–645 (2000).
   PubMed Web of Science ®Google Scholar
• Hoang-Xuan K, Capelle L, Kujas M et al. Molecular heterogeneity of oligodendrogliomas suggests alternative pathways in tumor progression. Neurology57, 1278–1281 (2001).
   PubMed Web of Science ®Google Scholar
• Lavon I, Zrihan D, Zelikovitch B et al. Longitudinal assessment of genetic and epigenetic markers in oligodendrogliomas. Clin. Cancer Res.13, 1429–1437 (2007).
   PubMedGoogle Scholar
• Ohgaki H, Eibl RH, Wiestler OD et al. p53 mutations in nonastrocytic human brain tumors. Cancer Res.51, 6202–6205 (1991).
   PubMed Web of Science ®Google Scholar
• Jenkins RB, Blair H, Ballman KV et al. A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma. Cancer Res.66, 9852–9861 (2006).
   PubMed Web of Science ®Google Scholar
• van den Bent MJ, Afra D, O de Wittle et al. Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial. Lancet366, 985–990 (2005).
   PubMed Web of Science ®Google Scholar
• Shaw EG, Dumas-Duport C, Scheithauer BW et al. Radiation therapy in the management of low-grade supratentorial astrocytomas. J. Neurosurg.70, 853–861 (1989).
   PubMed Web of Science ®Google Scholar
• Ulmer JL, Salvan CV Mueller WM et al. The role of diffusion tensor imaging in establishing the proximity of tumor borders to functional brain systems: implications for preoperative risk assessments and postoperative outcomes. Technol. Cancer Res. Treat.3, 567–576 (2004).
   PubMedGoogle Scholar
• Keles GE, Lamborn KR, Berger MS. Low-grade hemispheric gliomas in adults: a critical review of extent of resection as a factor influencing outcome. J. Neurosurg.95, 735–745 (2001).
   PubMed Web of Science ®Google Scholar
• Berger MS, Deliganis AV, Dobbins J, Keles GE. The effect of extent of resection on recurrence in patients with low grade cerebral hemisphere gliomas. Cancer74, 1784–1791 (1994).
   PubMed Web of Science ®Google Scholar
• Schmidt MH, Berger MS Lamborn KR et al. Repeated operations for infiltrative low-grade gliomas without intervening therapy. J. Neurosurg.98, 1165–1169 (2003).
   PubMed Web of Science ®Google Scholar
• Recht LD, Lew R, Smith TW. Suspected low-grade glioma: is deferring treatment safe? Ann. Neurol.31, 431–436 (1992).
   PubMed Web of Science ®Google Scholar
• Karim AB, Maat B, Hatlevoll R et al. A randomized trial on dose-response in radiation therapy of low-grade cerebral glioma: European Organization for Research and Treatment of Cancer (EORTC) Study 22844. Int. J. Radiat. Oncol. Biol. Phys.36, 549–556 (1996).
   PubMed Web of Science ®Google Scholar
• Karim AB, Afra D, Cornu P et al. Randomized trial on the efficacy of radiotherapy for cerebral low-grade glioma in the adult: European Organization for Research and Treatment of Cancer Study 22845 with the Medical Research Council study BRO4: an interim analysis. Int. J. Radiat. Oncol. Biol. Phys.52, 316–324 (2002).
   PubMed Web of Science ®Google Scholar
• Fisher BJ, Leighton CC, Vujovic O, Macdonald DR, Stitt L. Results of a policy of surveillance alone after surgical management of pediatric low grade gliomas. Int. J. Radiat. Oncol. Biol. Phys.51, 704–710 (2001).
   PubMedGoogle Scholar
• Vigliani MC, Sichez N, Poisson M, Delattre JY. A prospective study of cognitive functions following conventional radiotherapy for supratentorial gliomas in young adults: 4-year results. Int. J. Radiat. Oncol. Biol. Phys.35, 527–533 (1996).
   PubMedGoogle Scholar
• Kiebert GM, Curran D, Aaronson NK et al. Quality of life after radiation therapy of cerebral low-grade gliomas of the adult: results of a randomised Phase III trial on dose response (EORTC trial 22844). EORTC Radiotherapy Co-operative Group. Eur. J. Cancer34, 1902–1909 (1998).
   PubMed Web of Science ®Google Scholar
• Surma-aho O, Niemela M, Vikki J et al. Adverse long-term effects of brain radiotherapy in adult low-grade glioma patients. Neurology56, 1285–1290 (2001).
   PubMed Web of Science ®Google Scholar
• Postma TJ, Klein M, Verstappen CC et al. Radiotherapy-induced cerebral abnormalities in patients with low-grade glioma. Neurology59, 121–123 (2002).
   PubMed Web of Science ®Google Scholar
• Correa DD, Deangelis LM, Shi W et al. Cognitive functions in low-grade gliomas: disease and treatment effects. J. Neurooncol.81, 175–184 (2007).
   PubMed Web of Science ®Google Scholar
• Taphoorn MJ, Schiphorst AK, Snoek FJ et al. Cognitive functions and quality of life in patients with low-grade gliomas: the impact of radiotherapy. Ann. Neurol.36, 48–54 (1994).
   PubMed Web of Science ®Google Scholar
• Klein M, Heimans JJ, Aaronson NK et al. Effect of radiotherapy and other treatment-related factors on mid-term to long-term cognitive sequelae in low-grade gliomas: a comparative study. Lancet360, 1361–1368 (2002).
   PubMed Web of Science ®Google Scholar
• Laack NN, Brown PD, Ivnik RJet al. Cognitive function after radiotherapy for supratentorial low-grade glioma: a North Central Cancer Treatment Group prospective study. Int. J. Radiat. Oncol. Biol. Phys.63, 1175–1183 (2005).
   PubMedGoogle Scholar
• Eyre HJ, Crowley JJ, Townsend JJ et al. A randomized trial of radiotherapy versus radiotherapy plus CCNU for incompletely resected low-grade gliomas: a Southwest Oncology Group study. J. Neurosurg.78, 909–914 (1993).
   PubMed Web of Science ®Google Scholar
• Shaw EG, Berkey B, Coons SW et al. Initial report of Radiation Therapy Oncology Group (RTOG) 9802: prospective studies in adult low-grade glioma (LGG). J. Clin. Oncol.24, S18 (2006).
   Google Scholar
• van den Bent MJ, Kros JM, Heimans JJ et al. Response rate and prognostic factors of recurrent oligodendroglioma treated with procarbazine, CCNU, and vincristine chemotherapy. Dutch Neurooncology Group. Neurology51, 1140–1145 (1998).
   PubMed Web of Science ®Google Scholar
• van den Bent MJ, Keime-Guibert F, Brandes AA et al. Temozolomide chemotherapy in recurrent oligodendroglioma. Neurology57, 340–342 (2001).
   PubMed Web of Science ®Google Scholar
• Pace A, Vidiri A, Galie E et al. Temozolomide chemotherapy for progressive low-grade glioma: clinical benefits and radiological response. Ann. Oncol.14, 1722–1726 (2003).
   PubMed Web of Science ®Google Scholar
• van den Bent MJ, Chinot O, Boogerd W et al. Second-line chemotherapy with temozolomide in recurrent oligodendroglioma after PCV (procarbazine, lomustine and vincristine) chemotherapy: EORTC Brain Tumor Group Phase II study 26972. Ann. Oncol.14, 599–602 (2003).
   PubMed Web of Science ®Google Scholar
• Quinn JA, Reardon DA, Friedman AH et al. Phase II trial of temozolomide in patients with progressive low-grade glioma. J. Clin. Oncol.21, 646–651 (2003).
   PubMed Web of Science ®Google Scholar
• Soffietti R, Nobile M, Ruda R et al. Second-line treatment with carboplatin for recurrent or progressive oligodendroglial tumors after PCV (procarbazine, lomustine and vincristine) chemotherapy: a Phase II study. Cancer100, 807–813 (2004).
   PubMed Web of Science ®Google Scholar
• Levin N, Lavon I, Zelikovitsh B et al. Progressive low-grade oligodendrogliomas: response to temozolomide and correlation between genetic profile and O6-methylguanine DNA methyltransferase protein expression. Cancer106, 1759–1765 (2006).
   PubMed Web of Science ®Google Scholar
• van den Bent MJ, Taphoorn MJ, Brandes AA et al. Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971. J. Clin. Oncol.21, 2525–2528 (2003).
   PubMed Web of Science ®Google Scholar
• Brandes AA, Tosoni A, Cavallo G et al. Temozolomide (TMZ) 3 weeks on/1 week off in the treatment of progressive low grade gliomas: a Phase II GICNO study. J. Clin. Oncol.24, S18 (2006).
   Google Scholar
• Stege EM, Kros JM, de Bruin HG et al. Successful treatment of low-grade oligodendroglial tumors with a chemotherapy regimen of procarbazine, lomustine, and vincristine. Cancer103, 802–809 (2005).
   PubMed Web of Science ®Google Scholar
• Mason WP, Krol GS, Deangelis LM. Low-grade oligodendroglioma responds to chemotherapy. Neurology46, 203–207 (1996).
   PubMed Web of Science ®Google Scholar
• Buckner JC, Gesme D Jr, O’Fallon JR et al. Phase II trial of procarbazine, lomustine and vincristine as initial therapy for patients with low-grade oligodendroglioma or oligoastrocytoma: efficacy and associations with chromosomal abnormalities. J. Clin. Oncol.21, 251–255 (2003).
   PubMed Web of Science ®Google Scholar
• Hoang-Xuan K, He J, Huguet S et al. Temozolomide as initial treatment for adults with low-grade oligodendrogliomas or oligoastrocytomas and correlation with chromosome 1p deletions. J. Clin. Oncol.22, 3133–3138 (2004).
   PubMed Web of Science ®Google Scholar
• Pouratian N, Gasco J, Sherman JH, Shaffrey ME, Schiff D. Toxicity and efficacy of protracted low dose temozolomide for the treatment of low grade gliomas. J. Neurooncol.82, 281–288 (2007).
   PubMed Web of Science ®Google Scholar
• Lebrun C, Fontaine D, Bourg V et al. Treatment of newly diagnosed symptomatic pure low-grade oligodendrogliomas with PCV chemotherapy. Eur. J. Neurol.14, 391–398 (2007).
   PubMedGoogle Scholar
• Kaloshi G, Benouaich-Amiel A, Diakite F et al. Temozolomide for low-grade gliomas: predictive impact of 1p/19q loss on response and outcome. Neurology68, 1831–1836 (2007).
   PubMed Web of Science ®Google Scholar